Currently only small numbers of ASCVD patients achieve target LDL-c levels due to certain issues surrounding lipid lowering therapy. Prof. John Kastelein discusses the role of PCSK9 inhibition and future perspectives on lipid lowering.
This lecture by prof. John Kastelein was part of a CME accredited symposium: "PCSK9 inhibition: Science, outcomes and guidance" held at ESC 2018 in Munich, Germany.
Prof. John Kastelein , MD – Professor of Medicine, Department of Vascular Medicine at the Amsterdam University Medical Centers (AUMC) of the University of Amsterdam, The Netherlands, where he holds the Strategic Chair of Genetics of Cardiovascular Disease
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Amgen and Sanofi-Regeneron.The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- PCSK9 Inhibition: Science, Outcomes & GuidancePCSK9 as target for treatment: The genetic validation
Prof. Brian Ference, MD
- PCSK9 Inhibition: Science, Outcomes & GuidanceNovel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY
Prof. Jennifer Robinson, MD